Clinical Research Directory

Inclusion Criteria: 1. Histological confirmation of prostate malignancy 2. Patient must have had their primary PCa treated with surgery and/or radiation therapy; salvage radiation to the prostate bed or pelvis is allowed 3. Patient must be ≥ 18 years of age 4. Patient must have an Eastern Cooperative Oncology Group performance status ≤ 2 5. For patients treated with radical prostatectomy: arise of PSA ≥ 0.2 ng/mL (performed in the last month) or a rise of 2 ng/mL or more above the nadir PSA after definitive radiation therapy defined by two subsequent PSA assessments performed over a 3-month period in the same laboratory 6. Absence of any of the exclusion criteria 7. Signed informed consent Exclusion Criteria: 1. Absence of any of the inclusion criteria; 2. More than 3 years of androgen deprivation therapy (ADT), with less than 3 months from the last treatment 3. Spinal cord compression or impending spinal cord compression 4. Receipt of any other investigational agents in the previous 3 months 5. Inability to lie flat during or tolerate PET/CT 6. Hypersensitivity to active substance or any of excipients of Investigational Medicinal Product or Comparator 7. Life expectancy \<6 months 8. ECOG performance status \>2 9. Refusal to sign informed consent 10. Participation in a concurrent clinical trial 11. Concomitant active malignancy 12. Subject deprived of its freedom by administrative or legal decision or who is under guardianship